Selected Realized Investments

Focusing on the discovery, development and commercialization of innovative treatments to serve unmet medical needs. (SWX: ATLN)
Focused on the prevention of disease through innovative vaccines. (Acquired by MedImmune)
Cellective Therapeutics
Novel therapeutic antibodies for cancer and autoimmune diseases. (Acquired by MedImmune)
Civitas Therapeutics
Developing and commercializing transformative therapeutics using proprietary technology, focus on treating Parkinson’s disease. (ACQR, Acquired by Acorda Therapeutics)
Drugs for pulmonary diseases, including Ventavis for pulmonary arterial hypertension. (COTX, Acquired by Actelion)
Durata Therapeutics
Addressing the need for new antibiotics to treat infectious diseases. Durata’s lead product candidate, Dalbavancin, was approved by the FDA. (Acquired by Actavis)
Hyperion Therapeutics
Focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. (NADSAQ: HPTX)
Small molecule oncology drugs targeting the pi3Kinase/ mTor pathway. (Acquired by Takeda)
Products for antibiotic-resistant infectious diseases, including Esbriet for idiopathic pulmonary fibrosis. (ITMN, Acquired by Roche)
Kosan Biosciences
Novel polyketides for development as potential therapeutics. (KOSN, Acquired by Bristol-Meyers Squibb)
Labrys Biologics
Focused on treatments for chronic and episodic migraine. (Acquired by TEVA)
Millennium Pharmaceuticals
Therapeutic drug development. (NASDAQ: MLNM)
Development of Resolor for the symptomatic treatment of chronic constipation. (MOVE, Acquired by Shire)
NextWave Pharmaceuticals
Therapeutics approved for the treatment of pediatric ADHD. (Acquired by Pfizer)
Focused on the treatment of obesity. (NASDAQ: OREX)
Focused on innovative products addressing significant benign gynecological conditions and infertility. (Acquired by Gideon Richter)
Developing drugs for chronic disorders of the central nervous system, such as chorea associated with Huntington's disease. (Acquired by Biovail)
Salveo Specialty Pharmacy
Leading specialty pharmacy, offers medication and clinical services to patients with chronic conditions. (Acquired by Catamaran)
SARcode Bioscience
Therapeutics targeting dry eye disease. (Acquired by Shire)
Seattle Genetics
Developing antibodies and antigens (ADC's) for the treatment of cancer. (NASDAQ: SGEN)
Developing cancer therapeutics and oncology supportive care products that are safer and more effective than existing treatments. (NASDAQ: TSRO)
Threshold Pharmaceuticals
Develop therapeutic agents that selectively target tumor cells for the treatment of cancer. (NASDAQ: THLD)
Trius Therapeutics
Antibiotics for gram-positive bacterial infections, including those caused by MRSA. (TSRX, Acquired by Cubist)
Vicept Therapeutics
Developing treatment for skin redness associated with rosacea, actinic solar purpura and peri-procedural bruising of the skin. (Acquired by Allergan)